Alternatives to Inspirata

Omda Cytodose, an oncology medication management solution from Omda, employs clinically validated protocols along with patient-specific parameters to ensure safer and more effective treatments for individuals battling cancer. This innovative system enhances the quality of care provided to oncology patients by fostering a seamless and collaborative treatment process among healthcare professionals, including doctors, pharmacists, and nurses. Omda Cytodose is designed to support a comprehensive range of adult and pediatric cancers, accommodating various medical treatments such as chemotherapy, immunotherapy, hormone therapy, and additional supportive medications. Initially created by a team of clinicians at one of Norway's premier cancer centers and introduced in 2001, Omda Cytodose has gained widespread adoption across healthcare regions in the Nordic countries, leading to the fulfillment of millions of medication orders. With a robust 15-year history marked by stability, reliability, and safety, the system is meticulously configured with chemotherapy protocols that reflect both national and international guidelines. This ensures that patients receive the most up-to-date treatment options available, further enhancing their chances of successful outcomes.

Over 25 years ago, one of our founders was working as the IT Director of a large behavioural health and residential services agency in New York. Sensing a need for a better way to track and report on their services, he developed a case management system for his agency. Over time, two other agencies joined in and helped expand the software so that it could serve the needs of virtually any human services agency in the country. Today, Foothold’s team and our software support hundreds of agencies across the nation, in Guam, and in Puerto Rico. With our technology expertise and roots in human services, we continue to empower agencies to focus on their missions.

No matter the scale of your clinic or your location, MOSAIQ Plaza* equips you with the essential digital tools to provide exceptional multidisciplinary care for your patients—ensuring consistency, reliability, and security throughout their journey from diagnosis to survivorship while generating valuable real-world evidence. Elekta has introduced robust solution packages designed to boost your team's ability to provide care and optimize treatment workflows, allowing you to concentrate on your primary focus: your patients. As we pave the way for the future of multidisciplinary cancer care, MOSAIQ 3 establishes new benchmarks in oncology workflow and information management. Experience the advantages of effortless access to the MOSAIQ Plaza environment, which leads to remarkable efficiencies and a more streamlined operational experience, ultimately enhancing patient outcomes and satisfaction.

Carevive provides a cancer care management platform that is integrated with electronic health records (EHR) to improve patient outcomes across the entire cancer treatment process. This innovative platform streamlines treatment planning by gathering patient preferences, evaluating interests in clinical trials, and tackling both physical and psychosocial challenges to enhance decision-making processes. During the active treatment phase, Carevive supports remote monitoring of symptoms through electronic patient-reported outcomes (ePROs), offering personalized symptom management plans and evidence-based pathways that aim to elevate quality of life and minimize hospital admissions. After treatment concludes, the platform continues to monitor patient-reported late effects and organizes essential care, which includes diagnostic assessments to identify new or recurring cancers. Furthermore, Carevive's analytics provide insights into aggregated patient experience data, aiding in ongoing quality enhancement and contributing to practical research in oncology. This comprehensive approach ensures that patients receive holistic support throughout their cancer journey, ultimately leading to better health outcomes.

Paige's offerings have the potential to revolutionize the practice of pathologists by instilling greater certainty in diagnoses. The company is committed to pioneering a new era of clinical tools and predictive assessments that empower pathologists while redefining the field of oncology. With its innovative AI solutions, Paige paves the way for the future of pathology. The Paige Platform serves as a comprehensive, secure solution that ensures interoperability with laboratory information systems (LIS), integrates multiple scanners, offers cloud storage, facilitates case management, enables image review through FullFocus®, and incorporates advanced AI applications. The Paige Prostate suite of AI tools is specifically designed to aid pathologists in identifying suspicious areas, grading and quantifying tissue samples, and assessing perineural invasion (PNI) in prostate needle core biopsies. Similarly, the Paige Breast suite of AI applications supports pathologists in evaluating breast cancer by enabling the identification of malignancies in breast biopsies and the detection of metastases in lymph nodes associated with breast tissue. Collectively, these advancements not only enhance diagnostic accuracy but also improve patient outcomes in oncology.

Enhancing the care quality and outcomes for individuals battling cancer necessitates a cooperative effort among healthcare providers, researchers, cancer institutions, and the patients themselves. Oncora's user-friendly software platform empowers all parties involved to gather and utilize real-world data, thereby facilitating informed healthcare decisions that prioritize patient welfare. Our solutions are specifically designed for healthcare professionals who are committed to advancing cancer treatment results. By simplifying workflows, alleviating documentation challenges, and optimizing care through smart software solutions, we enable a more efficient healthcare experience. Our intuitive tools allow for the capture and visualization of regulatory-grade real-world data, essential for informed decision-making. With sophisticated reporting capabilities, you can measure quality and enhance operations to elevate patient care. Engaging in rigorous clinical research alongside leading cancer care experts further reinforces our commitment. The intuitive, web-based software we offer is tailored to meet the needs of your cancer center, providing data and tools that expedite clinical breakthroughs and innovations. Ultimately, our mission is to transform cancer care through technology and collaboration, ensuring that patients receive the highest standard of care available.

VSClinical facilitates the clinical analysis of genetic variants in accordance with ACMG and AMP guidelines. Its structured workflow supports adherence to the American College of Medical Genetics (ACMG) standards, which are essential for identifying and categorizing pathogenic variants related to inherited disease risk, cancer susceptibility, and rare disease diagnosis. The combined ACMG/AMP guidelines for variant interpretation establish a framework for scoring variants and categorizing them into one of five classification levels. Implementing these guidelines necessitates a thorough examination of annotations, genomic contexts, and pre-existing clinical insights for each variant. VSClinical streamlines this process by offering a customized workflow that evaluates each relevant criterion and supplies comprehensive bioinformatics, literature references, and clinical knowledgebase evidence to aid in the scoring and interpretation of variants. This innovative approach is designed to enhance the efficiency of variant scientists as they navigate the complexities of variant processing and analysis. Overall, VSClinical stands out as a vital tool for accelerating the understanding and classification of genetic variants in clinical settings.

The ARIA® oncology information system is designed to assist both medical and radiation oncology practitioners, including those utilizing proton therapy. It enables the review of clinical images, prescriptions, lab results, quality assurance, treatment outcomes, and much more. Additionally, it automates cancer staging in accordance with AJCC guidelines and allows for flexible management of treatment toxicities. With a strong emphasis on interoperability, ARIA ensures that patient data can be utilized effectively across various devices and platforms. It provides comprehensive support for HL7 and DICOM standards, simplifying the transfer of patient data between healthcare facilities. This system grants your teams immediate access to patient information, enhancing their ability to plan and make real-time adjustments as needed. Furthermore, ARIA OIS aids in optimizing image-guided treatment techniques by utilizing radiographic, fluoroscopic, and cone-beam CT images. It also documents activities to support evidence-based Pay-for-Performance initiatives while ensuring compliance with HIPAA regulations. By efficiently storing and organizing patient data and images, ARIA enables your teams to remain informed and dedicated to providing high-quality care for their patients. This innovative system ultimately streamlines workflows, allowing healthcare providers to focus on what truly matters: patient outcomes and well-being.

Color delivers one of the most user-friendly, high-quality genetic testing services currently on the market, examining genetic markers linked to the likelihood of developing prevalent cancers and heart diseases, as well as how individuals metabolize specific medications. Our comprehensive range of services, tools, and expertise is designed to facilitate the enrollment of new patients and guide them through personalized care journeys that evolve over time. By taking a holistic approach to patient health, we integrate genetic data, personal and family medical histories, along with lifestyle and behavioral factors to identify and suggest tailored care options or solutions that align with each patient's unique risk profile. This multifaceted strategy ensures that patients receive relevant recommendations that can significantly impact their health outcomes.

Accelerating the speed, precision, and affordability of cancer diagnoses is crucial, especially considering that one in three individuals will face this disease in their lifetime. Unfortunately, the current diagnostic process is often hindered by slow and costly methods, primarily due to the lack of advanced automated tools that support healthcare professionals. Qritive addresses this challenge by offering an AI-driven solution designed to assist physicians in analyzing both microscopy images and textual patient data efficiently. This innovation not only enhances the effectiveness of hospitals in diagnosing cancer but also contributes to significant cost savings. Additionally, Pantheon serves as a CE-marked, vendor-agnostic digital pathology platform that facilitates the complete digitization of pathology lab workflows and telepathology. It also supports comprehensive report generation and offers a robust platform for AI-driven analysis of whole-slide images in pathology. This technology is particularly adept at distinguishing between a variety of benign conditions and malignant diseases within breast tissue, which is vital for timely and accurate treatment. In doing so, it plays a pivotal role in transforming the landscape of cancer diagnostics.

Recursion is a leading TechBio innovator using artificial intelligence to radically improve how new medicines are discovered and developed. The company was founded on the idea that images of cells could be used to train AI systems to understand disease biology at scale. By combining data, machine learning models, and powerful computing, Recursion works to overcome the inefficiencies of traditional drug discovery. Its Recursion OS platform connects massive proprietary biological datasets with automated experimentation and AI-driven insights. This approach has produced a growing pipeline of potential therapies for oncology and rare diseases with high unmet medical needs. Recursion has demonstrated significant gains in speed, efficiency, and cost reduction compared to conventional pharmaceutical methods. Strategic partnerships with pharmaceutical companies and technology leaders expand the reach of its platform. The company also collaborates with NVIDIA to power its discovery efforts using BioHive-2, one of the most advanced supercomputers in biopharma. Together, these capabilities position Recursion as a leader in AI-driven drug discovery. Its ultimate goal is to deliver better medicines to patients through precision design and data-driven science.

Our software products are crafted for simplicity and quick comprehension. User-friendly interfaces, developed in collaboration with Oncologists, are designed to maximize efficiency and save valuable time. We implement robust systems aimed at improving patient safety while introducing innovative modules that push the boundaries of research. Automation is at the heart of our solutions, facilitating everything from chemotherapy order planning to staff management. We provide a thorough solution tailored for cancer centers, optimizing the Oncology workflow seamlessly. With our platform, generating accurate chemotherapy orders is a swift and uncomplicated process. Our extensive protocol library boasts over 1000 regularly updated protocols. The system automatically calculates and confirms drug doses and infusion rates while being rigorously tested and CE marked for quality assurance. All doses are verified twice, and checks for drug-drug and drug-allergy interactions are included. Patient-drug matching is enhanced through QR coded labels, significantly reducing medication errors. Users can conveniently view the active chemotherapy order, patient diagnosis and stage, the latest lab results, and the chemotherapy flowsheet all on a single screen, ensuring a comprehensive overview at a glance. This streamlined approach promotes efficiency and safety in Oncology practice.

Enhance the effectiveness and efficiency of cancer care throughout various healthcare environments. Developed in close partnership with cancer specialists, iKnowMedSM serves as an electronic health record (EHR) that seamlessly offers essential patient information precisely when it’s needed, accessible on nearly any device. Featuring the latest advancements in user interface design and an unparalleled mobile platform, iKnowMed EHR delivers extensive point-of-care treatment decision support alongside customizable features that easily fit into current workflows. Empower your patients with thorough clinical assistance by utilizing a constantly refreshed repository of oncology treatment protocols, drug availability, and clinical outcomes. Gain access to evidence-based clinical guidelines and pathways precisely when required, ensuring timely and effective decision-making. Furthermore, keep your treatment options current by integrating data on treatment expenses, insurance coverage, and reimbursement information, thereby supporting both patients and healthcare providers in navigating the complexities of cancer treatment. In doing so, practices can significantly improve patient outcomes and streamline the overall care process.

The LARVOL CLIN platform offers a robust suite of AI-driven data intelligence and analytics specifically designed for professionals in oncology and drug development, consolidating over 100,000 cancer clinical trials along with comprehensive results, digitized Kaplan-Meier curves, forest plots, and live social media feedback from a network of more than 5,000 oncologists. Users benefit from a unified interface that allows for searches by condition, intervention, or trial ID, complemented by expert-curated insights and visually engaging dashboards that facilitate informed decision-making. Additionally, the platform encompasses features such as conference tracking, extensive biomarker and diagnostics databases, and market intelligence reports sourced from over 25,000 entities, including regulatory communications, clinical trial registries, and various scientific congresses. Designed to aid pharmaceutical and biotech teams in deciphering trial outcomes, trends, mechanisms of action, biomarker identification, and disease pipelines, it employs advanced search filters, heat maps, and real-time alerts. This comprehensive approach ensures that users remain well-informed and equipped to make strategic decisions in a rapidly evolving field.

Aiforia provides advanced deep learning and cloud-based solutions to pathologists and researchers in both preclinical and clinical laboratories, enhancing their capabilities in image analysis and workflow efficiency. By enabling scientists to discover new disease biomarkers and assisting R&D professionals in accelerating the market introduction of innovative drugs, Aiforia plays a crucial role in improving cancer diagnostic accuracy while revolutionizing healthcare from the initial discovery phase through to diagnosis. For clinical pathology laboratories seeking to boost efficiency and elevate the precision of their diagnoses, the Aiforia Clinical Suites present a comprehensive range of AI-driven diagnostic tools, intelligent visualization, quality control, and automated pre- and post-screening functionalities. We are in the process of developing specialized Suites targeting some of the most common cancers globally and have achieved CE-IVD certification for our AI solutions in lung and breast cancer, positioning us as a leader in diagnostic innovation. Our commitment to enhancing patient outcomes through technology underscores the transformative potential of our offerings in the healthcare sector.

Ibex Medical Analytics stands at the forefront of AI-driven cancer diagnostics within the field of pathology. Our diverse team comprises entrepreneurs, data scientists, software engineers, and medical professionals united in our mission to revolutionize cancer diagnostics through artificial intelligence, ultimately enhancing patient care. As the volume of tests continues to rise annually, pathologists face significant challenges in delivering precise and timely analyses. To address this, Ibex harnesses the power of AI to create clinical-grade solutions that aim to identify cancer with the same level of accuracy as a human pathologist. The Galen Platform employs advanced algorithms to scrutinize images, detect and classify cancer in biopsy samples, and highlight other clinically significant findings, thereby assisting pathologists in minimizing diagnostic errors while streamlining their workflow. Notably, Ibex’s Galen™ Prostate and Galen™ Breast solutions represent the pioneering AI-based cancer detection tools integrated into routine clinical practice in pathology labs, showcasing proven efficacy in uncovering previously missed cancer cases. As we continue to innovate, our commitment to improving cancer detection and patient outcomes remains unwavering.

Numerous choices in cancer treatment are fraught with uncertainty, and existing resources fail to assist a significant number of patients effectively. As a result, this situation contributes to preventable fatalities and the loss of billions in healthcare expenditures. Our team, which consists of experts from both computer science and oncology, is dedicated to addressing the critical challenges in cancer care using artificial intelligence. We are developing clinical-grade deep learning models that evaluate individual patient profiles and offer valuable guidance to oncologists during their decision-making processes. By placing oncologists at the forefront of our AI development, we ensure that the insights generated are not only interpretable but also actionable. Collaborating with leading academic medical institutions and community oncologists, we aim to tackle important clinical questions to improve patient outcomes. Ultimately, our goal is to enhance decision-making in cancer care and reduce the associated burdens on patients and healthcare systems.

Volpara Health software is utilized by various facilities, including leading cancer screening centers in the United States, to facilitate the early detection of breast cancer. Mammography technologists depend on this software to enhance the quality of mammograms. Recognized as the most scientifically validated screening tool in the breast health sector, Volpara provides essential evidence at critical moments. It offers access to comprehensive patient data, enabling more accurate assessments of breast cancer risk. Each analyzed image contributes to refining our algorithms for early detection of the disease. Your support is crucial in promoting additional screening or genetic tests for patients. The platform allows for the creation of tailored worklists and reports according to individual preferences. Users can simultaneously view statistics and lists from a single interface, making the process more efficient. Communication can be standardized across patients, referrers, and insurers, ensuring clarity and consistency. Furthermore, it enhances the delivery of result letters by incorporating thumbnail images of mammograms, making the information more engaging and informative. This multifaceted approach ultimately promotes better patient care and outcomes in breast health.

The product evaluates a patient's risk level to create a tailored digital screening plan, ensuring more reliable follow-up recommendations and enhancing diagnostic accuracy. This strategy is particularly effective in identifying cancers in women who are at heightened risk. WRRisk integrates a fully digital breast cancer risk assessment that utilizes patient-completed digital forms alongside a density evaluation to generate a comprehensive risk scorecard. By automating numerous manual processes, such as form collection and letter creation, WRRisk streamlines the management of breast risk programs, eliminating the need for paper documentation. This innovative product empowers both patients and healthcare providers with essential information, enhancing the overall care experience. Additionally, WRRisk provides calculations for ten-year and lifetime risk, as well as assessments based on secondary density metrics.

VIPER streamlines the process of screening by automating remote patient identification right at the diagnosis stage and ensuring qualified enrollment. By leveraging artificial intelligence, VIPER efficiently matches patients to precision trials during a critical enrollment period by utilizing lab-agnostic genomic data, electronic medical records (EMR), and pathology information tailored to both the patient and the research requirements. The system employs a specialized matching engine that searches for the most suitable clinical trials corresponding to a patient's specific diagnosis at the moment they receive it. Additionally, through seamless workflow integration, VIPER provides real-time alerts regarding a patient’s eligibility for available trials, ensuring the entire care team is informed during this narrow enrollment timeframe. Furthermore, VIPER features interactive dashboards that offer extensive data mining capabilities, allowing for the aggregation of site and study-level patient data to effectively meet study key performance indicators (KPIs). This comprehensive approach not only enhances trial recruitment efficiency but also supports researchers in achieving their goals more effectively.

Transform your single-cell RNA sequencing data into actionable insights using Cellenics software, which is hosted by Biomage as a community instance of this open-source analytics tool developed at Harvard Medical School. This platform empowers biologists to delve into single-cell datasets without the need for coding, while facilitating collaboration between scientists and bioinformaticians. Within just a few hours, it can convert count matrices into publication-ready figures, integrating effortlessly into your existing workflow. Cellenics is designed to be fast, interactive, and user-friendly, as well as being cloud-based, secure, and scalable to meet various research needs. The community instance provided by Biomage is available at no cost for academic researchers working with smaller to medium-sized datasets, accommodating up to 500,000 cells. Currently, over 3000 academic researchers engaged in studies related to cancer, cardiovascular health, and developmental biology are utilizing this powerful tool. This collaborative environment not only enhances research capabilities but also accelerates the discovery process in various scientific fields.

AI plays a crucial role in identifying early-stage cancers, facilitating prompt interventions that enhance survival prospects. Cancer's intricate nature means that each type carries distinct characteristics, packed with extensive data that requires thorough analysis. This is where AI excels, leveraging its capabilities to process complex information, ultimately revealing insights that can significantly aid in cancer treatment strategies. Equipped with precise and relevant data, we take proactive steps in our battle against cancer. By utilizing AI, we are poised to make substantial strides in overcoming this disease. Our AI technology is designed to detect early-stage cancer with remarkable accuracy, achieving detection rates between 97-99%. It proficiently identifies ten of the most prevalent abnormalities found in chest x-rays, thus enhancing one of the most fundamental diagnostic tools. This innovation not only streamlines the radiology workflow but also alleviates the workload for radiologists. Lunit INSIGHT CXR successfully encompasses a wide range of findings, ensuring that we are prepared to tackle the challenges presented by cancer detection and treatment. The future of cancer care looks promising with AI at the forefront of these advancements.

Explore our efficient screening tools designed to identify patients at a high risk for breast, colorectal, and other types of cancer. Progeny Clinical streamlines the management of family histories, risk assessments, and treatment options for your patients. You can gather family history information online and automatically create pedigrees prior to the clinic appointment. Modify existing pedigrees or create new ones at any time. Execute validated hereditary cancer risk assessment models with a single click, eliminating the need to re-enter data. Simplify the process by ordering genetic testing through Ambry Genetics. Monitor and analyze results from any laboratory without leaving the software environment. Enhance efficiency by generating letters, consultation notes, reports, and documents using custom templates that incorporate patient data fields. Utilize pre-configured or tailored data input screens to swiftly create custom queries and spreadsheet reports. Moreover, you can integrate a hyperlink within your electronic medical record to conveniently access the patient’s latest pedigree. This innovative approach not only saves time but also optimizes patient care and enhances workflow efficiency.

Verana Health operates as a platform for real-world data that converts both structured and unstructured information from electronic health records into curated, de-identified, disease-focused data modules through its clinician-informed and AI-enhanced VeraQ population health data engine. By aggregating data from key collaborations with prominent medical registries, including the American Academies of Ophthalmology, Neurology, and Urological Association, the platform integrates insights from over 20,000 clinicians and approximately 90 million patient records, thereby supplying high-quality datasets in near real-time for the purposes of generating real-world evidence, identifying clinical trial sites and subjects, reporting clinician quality, and managing medical registries. Users can access this wealth of information through cloud services like AWS Data Exchange and Amazon Redshift, which provide self-service API access, a user-friendly dashboard, and tools for customizable cohort discovery. Furthermore, the system employs advanced AI and machine learning algorithms along with comprehensive data quality assessments to ensure the reliability and accuracy of the information provided. This innovative approach not only facilitates efficient data utilization but also enhances the overall quality of healthcare research and practice.

ConcertAI stands out as a prominent provider of AI-driven solutions within the healthcare sector, particularly in the field of oncology. Their core mission revolves around enhancing patient outcomes and expediting insights by leveraging top-tier real-world data, cutting-edge AI technologies, and deep scientific knowledge. The company presents an array of products and services aimed at improving both clinical research and patient care experiences. Their Real-World Data Products deliver extensive, customized datasets that cater to diverse research needs across various enterprises. By simplifying clinical trial processes, their digital trial solution ensures efficiency, while the Clinical Trial Optimization (CTO) platform employs extensive AI capabilities to refine the design and implementation of trials specifically in oncology and hematology. Additionally, in partnership with NeoGenomics, ConcertAI has introduced CTO-H, a software-as-a-service (SaaS) solution that concentrates on hematological malignancies, providing sophisticated research analytics and optimizing operational workflows. This integration of advanced technologies not only enhances research capabilities but also significantly contributes to the advancement of patient care in complex medical fields.

Speeding up the creation of crucial medications and ensuring that patients worldwide can access top-notch cancer treatment and research equally. Our technology is transforming how patients access cutting-edge medicines and participate in clinical trials. FICS is a groundbreaking software solution that facilitates the gathering of regulatory-compliant data throughout patient treatment. By integrating previously isolated and non-interacting applications into a comprehensive, seamless platform, FICS is making clinical trials more efficient, quicker, and of superior quality, ultimately enhancing patient outcomes in significant ways.

Providers and healthcare plans are facing increasing demands to enhance the quality and affordability of comprehensive care for their most vulnerable and complex patient populations. We are here to assist in addressing the cumbersome processes, fragmented care teams, and isolated data systems that hinder the delivery of integrated care for the whole individual while adapting to new value-based care requirements, including those pertaining to behavioral health and social determinants of health. Currently, our nation allocates $33 billion each year to preventable hospital admissions stemming from inadequate care coordination and management of transitions, highlighting the urgent need for effective solutions. CareEmpower stands out as a comprehensive solution unlike any other care navigation system you've experienced. Whether your organization seeks to swiftly advance its Medicare Advantage program or establish a strong population health initiative for at-risk groups, CareEmpower offers the essential tools required. It effectively stratifies and prioritizes care opportunities for these vulnerable populations, ensuring that their needs are met in a timely and efficient manner. With our innovative approach, the path to better care coordination is clearer than ever.

Mamosis offers a cutting-edge AI-powered cancer diagnosis solution that accelerates and improves diagnostic accuracy by analyzing complex medical images and wellness metrics. The platform’s deep learning algorithms, developed with input from clinical experts, identify subtle patterns and anomalies that aid in early cancer detection. Mamosis delivers detailed, easy-to-interpret reports quickly, allowing clinicians to initiate timely interventions. The user-friendly interface streamlines the diagnostic process, enabling secure uploads and fast analysis, saving valuable time in clinical settings. With stringent data encryption and privacy protocols, patient information is protected at every step. Mamosis not only aids medical professionals but also empowers individuals by providing personalized health insights for proactive wellness management. The software integrates seamlessly into existing workflows, enhancing efficiency without disrupting daily operations. By fostering collaboration between AI and human expertise, Mamosis drives more accurate diagnoses and improved patient care.

Maximize the potential of your data to enhance the experiences of both your clinic and your patients. InSightive converts your oncology data into actionable insights that can be implemented immediately. By normalizing and structuring your data through oncology-specific relationships, you can achieve greater clarity and precision. Utilizing industry-leading Tableau visualization, our platform offers analytics tailored to the oncology field, boosting clinical performance significantly. InSightive can be accessed through ARIA, a standalone desktop application, or virtually any web browser. Kickstart your journey with readily customizable templates that focus on payer mix, referral sources, and operational efficiency. Swiftly aggregate activity data to uncover valuable operational insights, enabling you to examine your information in innovative and meaningful ways. Experience rapid query results that allow for treatment or policy adjustments within hours instead of days. This empowers your patients to benefit from the collective experiences of previous patients. Additionally, our data specialists are available to assist you in seamlessly incorporating Varian into your existing workflow, ensuring that you can leverage the full power of your oncology data for improved patient care. With InSightive, the future of oncology data management is at your fingertips.

Noona® offers a comprehensive management solution for patient outcomes that actively involves patients in their treatment through immediate symptom reporting and monitoring, enhanced clinical workflows that support evidence-based practices, and access to extensive data insights for improved ongoing care management. Patients have the freedom to report their symptoms, fill out questionnaires, and engage with their healthcare teams whenever they wish. This approach enables care teams to gather highly specific and detailed data tailored to each patient's diagnosis and treatment plan, facilitating better-informed decision-making. With the benefit of automated prioritization, healthcare providers can identify and respond to patients who require urgent attention. The platform features over 31 treatment modules that encompass more than 97 prevalent cancer types, complemented by 244 algorithms that assess symptom severity according to established guidelines. Additionally, its remote deployment capabilities ensure quick implementation and immediate access for patients to start using the system. This innovative solution ultimately enhances the overall quality of patient care and outcomes throughout the treatment journey.

Deeplink Medical has centered its offerings around the MIRIO platform, which is designed to cater to the varying use cases and requirements of stakeholders engaged in medical imaging within oncology, both in clinical settings and routine practice. Our services encompass three distinct yet interconnected solutions: MIRIO, which tracks evaluations of solid tumors and monitors the therapeutic responses of oncology patients; a streamlined patient pathway that bridges hospital facilities with private medical practices; and an Imaging CRO dedicated to the oversight of imaging data in oncological clinical trials. The development of our innovative solutions is bolstered by a scientific board, ensuring a robust foundation for our offerings. Additionally, our collaborative workflow platform organizes imaging data and radiological assessments for patients with solid tumors, facilitating real-time data structuration in accordance with RECIST 1.1 and iRECIST guidelines right from the moment the data is generated at investigation sites. This enables immediate evaluation of treatment responses based on established international standards, ultimately enhancing the quality and efficiency of patient care in oncology. By integrating these services, we aim to provide a comprehensive approach that supports healthcare professionals in delivering optimal treatment outcomes.

Enhance the Patient Journey by actively engaging, educating, and empowering individuals through improved health communications. Utilize a Patient Engagement Platform to tailor optimal care plans for various medical pathways, such as prostate and breast cancer. Develop a Patient Engagement Pathway that organizes communication strategies in accordance with each care plan's requirements. Streamline the organization of communications by creating or sourcing a variety of supportive materials, including messages, documents, and videos, that correspond to different phases of the care plan. Establish clear communication rules that specify who receives which communications and at what times, ensuring timely delivery of essential information. Integrate new patients into the system effortlessly by matching their specific needs with the appropriate pathway. Finally, centralize all patient-facing communications in one location, allowing for the efficient dissemination of messages, documents, forms, videos, and health widgets. By doing so, healthcare providers can enhance the overall patient experience and foster better health outcomes.

Achieve a comprehensive understanding of your research operations by utilizing a robust and standardized clinical trial management system that has been developed in partnership with prominent academic medical and cancer centers. Streamline billing designation processes to promote uniformity across various teams and systems. Enhance your budgeting strategies, ensure accurate routing of charges, and perform more effective audits and monitoring of billing compliance. This integrated approach provides deep visibility and insight into all elements of clinical research, particularly in financial management, thanks to collaboration with elite research institutions. Moreover, by connecting OnCore with your existing electronic medical records (EMR), including seamless integrations with Epic and Cerner, you can significantly boost patient safety, minimize redundant data entry, improve billing compliance, and elevate overall operational efficiency. Ultimately, this system not only simplifies processes but also fosters a more effective research environment.

Charm Evolution serves as a comprehensive oncology information management system that centralizes all processes related to chemotherapy prescribing and administration, thereby improving safety, consistency, and accountability by substituting handwritten orders with digital prescriptions that are meticulously monitored through order adjustments and orphan management for precise wastage reporting. It consolidates accurate and secure patient records and treatment data from various sources into a unified database, facilitating informed and efficient decision-making directly at the point of care. Furthermore, an intelligent pathway engine automates treatment protocols, enhances scheduling in accordance with regimens, and caters to both adult and pediatric oncology and hematology through customizable treatment libraries, protocol validation, and management of clinical trials. Additionally, integrated pharmacy management offers bi-directional connectivity with compounders, along with the option to customize worksheets and labels, while the scheduling component maximizes resource allocation and minimizes the need for patient travel, ultimately contributing to a more effective healthcare delivery system. This holistic approach fosters an environment where healthcare providers can deliver optimal care to their patients.

PacBio (Pacific Biosciences) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The Revio system adds affordability, high throughput, and ease of use to a foundation of long reads, exceptional accuracy, and direct methylation detection. The Onso system is an innovative benchtop short-read DNA sequencing platform with an extraordinary level of accuracy using PacBio sequencing by binding. Software tools for Sequel II/IIe and Revio systems designed to set up and monitor long-read HiFi sequencing runs, review performance metrics, analyze, visualize, and annotate sequencing data.

Azenta Life Sciences delivers versatile, robust, and scalable informatics solutions for sample processing, allowing laboratories to effectively implement systems across various locations while leveraging integrated project and diagnostic management capabilities. Our unmatched sample exploration and management tools are designed to expedite your processes in discovery, development, and delivery. Additionally, Azenta Life Sciences provides cloud-driven informatics solutions that streamline laboratory workflows and enhance staff efficiency through standardized procedures. The software encompasses various modules that oversee clinical trials, patients and families, informed consent, storage, diagnostics, next-generation sequencing, and sample handling. It also features connectivity with external data sources and offers adaptable options for incorporating third-party systems and instruments, ensuring a comprehensive approach to laboratory management. This enables laboratories to maintain a high level of accuracy and efficiency in their operations.

Flatiron Health's Evidence Solutions provide a versatile method for generating real-world evidence, both prospective and retrospective, which aids life sciences companies in efficiently meeting their oncology research objectives. At the heart of these offerings is Flatiron Horizon, a comprehensive platform that combines a rich database of more than 5 million anonymized patient records and 1.5 billion data points, coupled with advanced curation techniques and disease-specific machine learning models. This innovative platform is designed to facilitate various phases of the biopharma lifecycle, including discovery, clinical study design, regulatory submissions, and post-marketing commitments. Furthermore, Flatiron's services deliver customized real-world data configurations that cater specifically to oncology, enabling prospective evidence generation through minimally invasive studies and optimizing protocols for better patient identification. Additionally, the platform ensures a streamlined transfer of data from electronic health records to electronic data capture systems with the functionality of Flatiron Clinical Pipe, enhancing overall research efficiency and effectiveness. Such capabilities position Flatiron Health as a leader in transforming oncology research through the power of real-world data.

Efficiently generating reports for NGS-based clinical tests necessitates a well-established and sophisticated platform that can automatically prioritize variants, interpret clinical data, and create comprehensive reports. Strand Omics serves as a rapid, HIPAA-compliant cloud platform that enhances our clinical diagnostics efforts, having been refined over four years through the analysis of more than 10,000 clinical reports and numerous peer-reviewed studies. This platform integrates advanced bioinformatics algorithms with curated databases, intuitive visualization tools, and robust reporting features. It is designed with specialized workflows tailored for both rare inherited conditions and somatic tumor profiling assays. Additionally, the system boasts a library of over 10,000 somatic variants that have been curated for their oncogenic potential, alongside 100 genes selected for their druggability across various cancer types, as well as 500 drugs that have been validated for efficacy against multiple cancers. Furthermore, its comprehensive approach ensures that healthcare professionals have access to critical data, ultimately facilitating informed decision-making in patient care.

Mosio allows research teams to improve subject adhesion, communications, data collection, and communication on mobile's most popular channel, text messaging. Our software helps research teams communicate more efficiently with participants by delivering interactive elements to mobile phones and messaging automation. WHO CAN WE HELP? + Clinical Trial Sponsors (Pharma & Biotech) + Cancer Centers and Clinical Research Organizations + NIH-Funded Studies + Public Health Agencies + Clinical Trial Managers/Directors and Clinical Operations Managers/Directors. Clinical Project Managers. Principal Investigators. Clinical Research (Study). Coordinators. All research staff who regularly communicate with study participants. BENEFITS + Interactive medication reminders and medication compliance alerts + Automate data collection. + Increase engagement and adherence. + Get SMS appointment reminders to fix your no-show problem. + Increase retention with automated check ins

Our worldwide data-sharing network produces actionable clinical insights from data aimed at enhancing patient outcomes on a global scale. SOPHiA GENETICS is dedicated to shaping the future of AI-enhanced medicine. By integrating various healthcare-omics data types, we are dismantling existing data barriers and creating machine learning models that yield insights capable of aiding healthcare professionals in elevating patient care. The updated interface, along with new features and advanced functionalities, will further expedite precision medicine workflows, bringing us closer to making data-driven healthcare accessible to all. Utilizing the power of AI and machine learning (ML), our cloud-based platform offers a secure and easily accessible space for the standardization, computation, and analysis of digital health data, which generates insights from intricate multimodal data sets that can significantly enhance diagnostic processes, therapy choices, analytical methods, and drug development initiatives. Moreover, our continuous evolution reflects our commitment to innovation in the healthcare sector.

We are at the forefront of precision medicine, alleviating the strain on healthcare systems through our innovative automated analysis, diagnosis, and treatment solutions that cater to healthcare providers and patients globally. Congenica emerged from groundbreaking research conducted at the Wellcome Sanger Institute and the UK's National Health Service. Our offerings integrate cutting-edge technology, top-tier automation, and artificial intelligence, allowing our distinct platform to be utilized across various human diseases where genomic information plays a crucial role in revealing actionable insights. As a digital health company, we specialize in software and solutions designed for the large-scale analysis and interpretation of genomic data. Our fully automated system, enhanced with robust APIs and machine learning capabilities, aims to lighten the load on specialist staff, improve case processing efficiency, speed up decision-making, and simplify reporting. Our platform is certified, accurate, and secure, empowering clinical decisions with the utmost confidence in the resulting clinical outcomes, and we continuously strive to innovate and expand our capabilities to meet the evolving needs of the healthcare landscape.

Efficiently merge the multiomic information of patients with their health records to provide more tailored care solutions. Implement specialized data repositories to facilitate extensive analyses and foster collaborative research initiatives on a population-wide scale. Expedite research processes by leveraging adaptable workflows and comprehensive computational tools. Ensure the safeguarding of patient privacy through adherence to HIPAA standards, complete with robust data access and logging mechanisms. AWS HealthOmics empowers healthcare and life science organizations, along with their software collaborators, to securely store, retrieve, and analyze diverse omics data, such as genomic and transcriptomic information, ultimately yielding valuable insights that enhance health outcomes and propel scientific advancements. Manage and evaluate omics data for extensive patient cohorts to discern how variations in omics relate to phenotypic expressions within the population. Develop consistent and accountable clinical multiomics workflows designed to minimize turnaround times while boosting efficiency. Seamlessly incorporate multiomic assessments into clinical trials aimed at evaluating new therapeutic candidates, thereby enhancing the overall drug development process. By harnessing these innovative approaches, organizations can ensure a deeper understanding of patient health and contribute to groundbreaking research findings.

Address the complexities of value-based care regardless of your existing EHR system. Gain a comprehensive understanding of your patient demographics through consolidated data from various sources, presented in an intuitive visual format. Leverage data-driven insights to enhance the management of chronic diseases and facilitate smoother transitions in care, while also working to prevent illnesses, reduce costs, and enhance care management initiatives. Promote effective care coordination through tools designed for a proactive mindset, including a pre-visit dashboard, risk assessment capabilities, and automated monitoring of admission, discharge, and transfer activities. Activate care management strategies to broaden the reach of healthcare providers. Encourage essential patient interactions and ensure meaningful follow-up between visits. Utilize the Johns Hopkins ACG system for risk stratification to pinpoint patients most at risk for high-cost healthcare utilization. Efficiently allocate resources to areas where they are most urgently needed. Aim to elevate performance metrics related to quality care. Engage successfully in value-based payment initiatives and maximize reimbursement opportunities as you navigate this evolving landscape. By implementing these strategies, healthcare organizations can improve patient outcomes and foster a more sustainable care environment.

Spend more quality time engaging with your patients while minimizing your interactions with electronic health records, as OncoEMR® prioritizes workflow efficiency and rapid processing. The platform is tailored for oncology practices, featuring specialized workflows and tools like Document Search that streamline tasks, cutting down work duration from minutes to mere seconds. With the introduction of MIPS, OncoEMR® provides essential resources to navigate the program successfully, assisting in the collection and reporting of mandatory data while offering support throughout the workflows and official reporting obligations. Designed specifically for community oncology practices, OncoEMR® incorporates elements such as NCCN Chemotherapy Order Templates® and the latest AJCC disease factors, transforming it into a bespoke diagnostic and treatment resource. Prior to launching OncoEMR®, Flatiron will handle the migration of your existing EHR database, allowing for a seamless transition on your first day of operation. After the migration process, you will benefit from over 150 preloaded reports, enabling you to gain valuable insights into both business operations and clinical metrics, including patient wait times, ensuring a comprehensive understanding of your practice's performance. This combination of tools and features not only enhances efficiency but also supports improved patient care and outcomes in your oncology practice.

Meeting the objectives of care coordination at a reduced cost is essential for enhancing patient satisfaction and fostering loyalty. However, these objectives are intricate. Your organization requires a population health software solution that offers a collaborative care plan, seamlessly integrated across all healthcare environments, without disrupting users' workflows. It’s vital to utilize automated outreach tools for patients, allowing care coordinators to focus on more strategic responsibilities. Now is the moment to consider Care Director. By implementing Care Director, your team can streamline the coordination of outpatient services, categorize patients into healthy and at-risk groups, and obtain care recommendations driven by actionable clinical insights, leading to timely interventions and better overall population health. Care Director empowers healthcare providers to view a comprehensive care plan directly within their existing workflows, facilitating easy access to information and enabling efficient communication back to care navigators with just a few clicks, ultimately transforming the care delivery process. With this approach, your organization can enhance operational efficiency and deliver a higher standard of care.